CHS-3351 (ranibizumab biosimilar) / Coherus Oncology - LARVOL DELTA

"$CHRS Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services https://t.co/mRlcdUKt4P" (@stock_titan)

Medicaid • Medicare • Reimbursement • US reimbursement

"$CHRS Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 https://t.co/vJfvSWzQCA" (@stock_titan)

Launch US

CHS-3351: Initiation of clinical development in 2018 (36th Annual J.P. Morgan Healthcare Conference, Coherus)

New trial • Biosimilar

CHS-3351: Initiation of clinical development in 2018 (36th Annual J.P. Morgan Healthcare Conference, Coherus)

New trial • Biosimilar

Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results (GlobeNewswire, Coherus BioSciences, Inc.) - "Guidance for the Next Twelve Months from December 31, 2018: UDENYCA™ (pegfilgrastim-cbqv)...Secure receipt of transitional pass-through status in 340-B hospitals in April 2019. Increase penetration of patient and provider support programs and access portals. Secure parity payment status with all national and local payers. CHS-1420 (adalimumab (Humira®) biosimilar): Pursue manufacturing objectives in support of the anticipated filing of a 351(k) biologic license application (BLA) in the U.S. CHS-3351 (ranibizumab (Lucentis®) biosimilar): Complete manufacturing technology transfer to support clinical development of CHS-3351."

Clinical